| Name | Title | Contact Details |
|---|
Contact Bridge Inc is a Surrey, BC-based company in the Business Services sector.
AnalyticsIQ is an offline marketing data creator and predictive analytics innovator. We are the first data company to consistently blend cognitive psychology with sophisticated data science to help you understand the who, what and why behind individuals and the decisions they make every day. Our accurate and comprehensive consumer database, PeopleCore, provides access to data attributes you cant find anywhere else. From demographics and affluence categories to psychological drivers and purchase predictors, marketers rely on our data to fuel personalized experiences across channels. And BusinessCore, our first-of-its-kind B2B database, provides unprecedented insight into not just businesses and accounts, but also individual employees. By going beyond firmographics and focusing on an employees role, purchasing style and communication, companies can accelerate their marketing and sales efforts while building long-standing customer relationship. Recognized as one of the Top 10 Most Innovative Companies in Georgia, AnalyticsIQ is headquartered in Atlanta, Georgia, and employs a team of industry veterans, data scientists and cognitive psychologists with over 100 years of collective analytical experience. Our fast and flexible approach makes it easy to get started using sophisticated data to grow your business.
Rrootshell is a Jacksonville, FL-based company in the Business Services sector.
CEPI – Coalition for Epidemic Preaparedness Innovations - is a new broad international coalition set up to fund development of vaccines against emerging infectious diseases with epidemic potential, where there are few market incentives. The epidemics like Ebola and SARS we have seen over the past years, have demonstrated the need for vaccines. Development of a vaccine takes many years, and it is too late to start when the outbreak has started. By having vaccines on the shelf ready for phase III early in an outbreak, we can demonstrate the vaccine efficacy and stop the outbreak while it is small. CEPI has already launched two calls for proposals; one for development of vaccines against MERS, Lassa and Nipah and one for the development of rapid response vaccine technology to enable development of vaccines against new and unknown diseases. CEPI was launched in January 2017 and now has funding totalling $620 million from soverign investors and philantropic institutions. CEPI`s investors are: The Governments of Australia, Belgium, Canada, Japan and Norway, as well as the Wellcome Trust and the Bill&Melinda Gates Foundation. In addition the European Commission will co fund activities with €250 million.